Daily Archives: March 3, 2012

BioLineRx Announces Publication of Pre-clinical Results Demonstrating Efficacy of BL-7010, an Oral Treatment for Celiac Disease and Gluten Sensitivity

- Just last week BioLineRx, a biopharmaceutical development company announced successful pre-clinical testing of a potentially revolutionary treatment for celiac disease.  This new treatment may help celiac disease patients reduce their gluten toxins to create an overall healthy body for all celiac disease patients. Jerusalem, Israel – February 21, 2012 – BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, ...

Read More »